Literature DB >> 27245329

Adherence to antithrombotic therapy guidelines improves mortality among elderly patients with atrial fibrillation: insights from the REPOSI study.

Marco Proietti1,2, Alessandro Nobili3, Valeria Raparelli4,5, Laura Napoleone4,5, Pier Mannuccio Mannucci6, Gregory Y H Lip7,8.   

Abstract

BACKGROUND: Atrial fibrillation (AF) is associated with a substantial risk of thromboembolism and mortality, significantly reduced by oral anticoagulation. Adherence to guidelines may lower the risks for both all cause and cardiovascular (CV) deaths.
METHODS: Our objective was to evaluate if antithrombotic prophylaxis according to the 2012 European Society of Cardiology (ESC) guidelines is associated to a lower rate of adverse outcomes. Data were obtained from REPOSI; a prospective observational study enrolling inpatients aged ≥65 years. Patients enrolled in 2012 and 2014 discharged with an AF diagnosis were analysed.
RESULTS: Among 2535 patients, 558 (22.0 %) were discharged with a diagnosis of AF. Based on ESC guidelines, 40.9 % of patients were on guideline-adherent thromboprophylaxis, 6.8 % were overtreated, and 52.3 % were undertreated. Logistic analysis showed that increasing age (p = 0.01), heart failure (p = 0.04), coronary artery disease (p = 0.013), peripheral arterial disease (p = 0.03) and concomitant cancer (p = 0.003) were associated with non-adherence to guidelines. Specifically, undertreatment was significantly associated with increasing age (p = 0.001) and cancer (p < 0.001), and inversely associated with HF (p = 0.023). AF patients who were guideline adherent had a lower rate of both all-cause death (p = 0.007) and CV death (p = 0.024) compared to those non-adherent. Kaplan-Meier analysis showed that guideline-adherent patients had a lower cumulative risk for both all-cause (p = 0.002) and CV deaths (p = 0.011). On Cox regression analysis, guideline adherence was independently associated with a lower risk of all-cause and CV deaths (p = 0.019 and p = 0.006).
CONCLUSIONS: Non-adherence to guidelines is highly prevalent among elderly AF patients, despite guideline-adherent treatment being independently associated with lower risk of all-cause and CV deaths. Efforts to improve guideline adherence would lead to better outcomes for elderly AF patients.

Entities:  

Keywords:  Antithrombotic therapy; Atrial fibrillation; Elderly; Guidelines; Outcomes

Mesh:

Substances:

Year:  2016        PMID: 27245329     DOI: 10.1007/s00392-016-0999-4

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  28 in total

1.  Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry.

Authors:  Emily C O'Brien; DaJuanicia N Holmes; Jack E Ansell; Larry A Allen; Elaine Hylek; Peter R Kowey; Bernard J Gersh; Gregg C Fonarow; Christopher R Koller; Michael D Ezekowitz; Kenneth W Mahaffey; Paul Chang; Eric D Peterson; Jonathan P Piccini; Daniel E Singer
Journal:  Am Heart J       Date:  2014-01-04       Impact factor: 4.749

2.  Polypharmacy, length of hospital stay, and in-hospital mortality among elderly patients in internal medicine wards. The REPOSI study.

Authors:  Alessandro Nobili; Giuseppe Licata; Francesco Salerno; Luca Pasina; Mauro Tettamanti; Carlotta Franchi; Luigi De Vittorio; Alessandra Marengoni; Salvatore Corrao; Alfonso Iorio; Maura Marcucci; Pier Mannuccio Mannucci
Journal:  Eur J Clin Pharmacol       Date:  2011-01-11       Impact factor: 2.953

Review 3.  Stroke prevention in atrial fibrillation: a systematic review.

Authors:  Gregory Y H Lip; Deirdre A Lane
Journal:  JAMA       Date:  2015-05-19       Impact factor: 56.272

4.  Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry.

Authors:  Gregory Y H Lip; Cécile Laroche; Mircea Iaochim Popescu; Lars Hvilsted Rasmussen; Laura Vitali-Serdoz; Gheorghe-Andrei Dan; Zbigniew Kalarus; Harry J G M Crijns; Mario Martins Oliveira; Luigi Tavazzi; Aldo P Maggioni; Giuseppe Boriani
Journal:  Europace       Date:  2015-08-30       Impact factor: 5.214

5.  Decision making for oral anticoagulants in atrial fibrillation: the ATA-AF study.

Authors:  Gualberto Gussoni; Giuseppe Di Pasquale; Giorgio Vescovo; Michele Gulizia; Giovanni Mathieu; Marino Scherillo; Domenico Panuccio; Donata Lucci; Carlo Nozzoli; Gianna Fabbri; Fabrizio Colombo; Letizia Riva; Concetta I Baldo; Aldo P Maggioni; Antonino Mazzone
Journal:  Eur J Intern Med       Date:  2013-05-16       Impact factor: 4.487

6.  Validation of a short Orientation-Memory-Concentration Test of cognitive impairment.

Authors:  R Katzman; T Brown; P Fuld; A Peck; R Schechter; H Schimmel
Journal:  Am J Psychiatry       Date:  1983-06       Impact factor: 18.112

7.  Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. The Euro Heart Survey on Atrial Fibrillation.

Authors:  Robby Nieuwlaat; S Bertil Olsson; Gregory Y H Lip; A John Camm; Günter Breithardt; Alessandro Capucci; Joan G Meeder; Martin H Prins; Samuel Lévy; Harry J G M Crijns
Journal:  Am Heart J       Date:  2007-06       Impact factor: 4.749

Review 8.  Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review.

Authors:  Yi Wan; Carl Heneghan; Rafael Perera; Nia Roberts; Jennifer Hollowell; Paul Glasziou; Clare Bankhead; Yongyong Xu
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2008-11-05

Review 9.  A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference.

Authors:  Paulus Kirchhof; Günter Breithardt; Jeroen Bax; Gerlinde Benninger; Carina Blomstrom-Lundqvist; Giuseppe Boriani; Axel Brandes; Helen Brown; Martina Brueckmann; Hugh Calkins; Melanie Calvert; Vincent Christoffels; Harry Crijns; Dobromir Dobrev; Patrick Ellinor; Larissa Fabritz; Thomas Fetsch; S Ben Freedman; Andrea Gerth; Andreas Goette; Eduard Guasch; Guido Hack; Laurent Haegeli; Stephane Hatem; Karl Georg Haeusler; Hein Heidbüchel; Jutta Heinrich-Nols; Francoise Hidden-Lucet; Gerd Hindricks; Steen Juul-Möller; Stefan Kääb; Lukas Kappenberger; Stefanie Kespohl; Dipak Kotecha; Deirdre A Lane; Angelika Leute; Thorsten Lewalter; Ralf Meyer; Lluis Mont; Felix Münzel; Michael Nabauer; Jens C Nielsen; Michael Oeff; Jonas Oldgren; Ali Oto; Jonathan P Piccini; Art Pilmeyer; Tatjana Potpara; Ursula Ravens; Holger Reinecke; Thomas Rostock; Joerg Rustige; Irene Savelieva; Renate Schnabel; Ulrich Schotten; Lars Schwichtenberg; Moritz F Sinner; Gerhard Steinbeck; Monika Stoll; Luigi Tavazzi; Sakis Themistoclakis; Hung Fat Tse; Isabelle C Van Gelder; Panagiotis E Vardas; Timo Varpula; Alphons Vincent; David Werring; Stephan Willems; André Ziegler; Gregory Y H Lip; A John Camm
Journal:  Europace       Date:  2015-10-18       Impact factor: 5.214

Review 10.  Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis.

Authors:  Felicita Andreotti; Bianca Rocca; Steen Husted; Ramzi A Ajjan; Jurrien ten Berg; Marco Cattaneo; Jean-Philippe Collet; Raffaele De Caterina; Keith A A Fox; Sigrun Halvorsen; Kurt Huber; Elaine M Hylek; Gregory Y H Lip; Gilles Montalescot; Joao Morais; Carlo Patrono; Freek W A Verheugt; Lars Wallentin; Thomas W Weiss; Robert F Storey
Journal:  Eur Heart J       Date:  2015-07-09       Impact factor: 29.983

View more
  22 in total

1.  Randomized controlled clinical trials versus real-life atrial fibrillation patients treated with oral anticoagulants. Do we treat the same patients?

Authors:  Paweł Balsam; Agata Tymińska; Krzysztof Ozierański; Martyna Zaleska; Katarzyna Żukowska; Katarzyna Szepietowska; Kacper Maciejewski; Michał Peller; Marcin Grabowski; Piotr Lodziński; Łukasz Kołtowski; Anna Praska-Ogińska; Inna Zaboyska; Janusz Bednarski; Krzysztof J Filipiak; Grzegorz Opolski
Journal:  Cardiol J       Date:  2018-11-08       Impact factor: 2.737

2.  Atrial fibrillation is highly prevalent yet undertreated in patients with biopsy-proven nonalcoholic steatohepatitis.

Authors:  Maureen Whitsett; Jane Wilcox; Amy Yang; Lihui Zhao; Mary Rinella; Lisa B VanWagner
Journal:  Liver Int       Date:  2018-12-21       Impact factor: 5.828

Review 3.  [Choosing wisely recommendations in cardiology].

Authors:  K Werdan; S Baldus; N Frey; U Nixdorff; K-H Kuck; H Katus
Journal:  Internist (Berl)       Date:  2017-06       Impact factor: 0.743

Review 4.  Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials?

Authors:  D Duerschmied; J Brachmann; H Darius; N Frey; H A Katus; W Rottbauer; A Schäfer; H Thiele; C Bode; Uwe Zeymer
Journal:  Clin Res Cardiol       Date:  2018-04-20       Impact factor: 5.460

Review 5.  Polypharmacy in older people: lessons from 10 years of experience with the REPOSI register.

Authors:  Pier Mannuccio Mannucci; Alessandro Nobili; Luca Pasina
Journal:  Intern Emerg Med       Date:  2018-08-31       Impact factor: 3.397

6.  Adherence as a language game.

Authors:  Espen Skarstein Kolberg
Journal:  Int J Clin Pharm       Date:  2017-03-02

7.  Appropriateness of prescription of oral anticoagulant therapy in acutely hospitalized older people with atrial fibrillation. Secondary analysis of the SIM-AF cluster randomized clinical trial.

Authors:  Stefania Antoniazzi; Ilaria Ardoino; Marco Proietti; Valter Monzani; Pier Mannuccio Mannucci; Alessandro Nobili; Carlotta Franchi
Journal:  Br J Clin Pharmacol       Date:  2019-07-19       Impact factor: 4.335

8.  Cardiac autonomic modulation impairments in advanced breast cancer patients.

Authors:  Claudia Arab; Luiz Carlos Marques Vanderlei; Laércio da Silva Paiva; Kyle Levi Fulghum; Carlos Elias Fristachi; Afonso Celso Pinto Nazario; Simone Elias; Luiz Henrique Gebrim; Celso Ferreira Filho; Yori Gidron; Celso Ferreira
Journal:  Clin Res Cardiol       Date:  2018-05-02       Impact factor: 5.460

9.  Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study.

Authors:  Valeria Raparelli; Daniele Pastori; Serena Francesca Pignataro; Anna Rita Vestri; Pasquale Pignatelli; Roberto Cangemi; Marco Proietti; Giovanni Davì; William Robert Hiatt; Gregory Yoke Hong Lip; Gino Roberto Corazza; Francesco Perticone; Francesco Violi; Stefania Basili
Journal:  Intern Emerg Med       Date:  2018-03-26       Impact factor: 3.397

10.  Appropriateness of oral anticoagulant therapy prescription and its associated factors in hospitalized older people with atrial fibrillation.

Authors:  Carlotta Franchi; Stefania Antoniazzi; Marco Proietti; Alessandro Nobili; Pier Mannuccio Mannucci
Journal:  Br J Clin Pharmacol       Date:  2018-06-19       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.